• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » PPD achieves CEO Cancer Gold Standard reaccreditation

PPD achieves CEO Cancer Gold Standard reaccreditation

July 23, 2015
CenterWatch Staff

Pharmaceutical Product Development (PPD) has achieved CEO Cancer Gold Standard reaccreditation from the nonprofit CEO Roundtable on Cancer for maintaining a strong commitment to the health of company employees.

PPD encourages employee participation in health and wellness programs, including cancer prevention and screening, nutrition coaching and fitness classes, to promote healthy lifestyles and empower employees to take an active role in managing their health.

“PPD is committed to the fight against cancer,” said David Simmons, chairman and chief executive officer of PPD. “As a global CRO with deep expertise in oncology, we are dedicated to helping biopharmaceutical clients deliver safe treatments to patients more quickly, cost-effectively and with the highest possible quality. We’re pleased the CEO Roundtable on Cancer has recognized our efforts in employee health and wellness, and we applaud their worthy mission.”

Hematology and oncology form one of PPD’s leading therapeutic areas for clinical research. PPD has conducted in excess of 420 hematology and oncology studies in the past five years at more than 23,000 research sites involving greater than 100,000 patients. PPD has a global network of more than 8,000 hematology and oncology investigators.

PPD provides a tobacco-free workplace, health screenings, education and promotion of healthy lifestyles and other initiatives critical to helping detect and prevent cancer.

The CEO Roundtable on Cancer developed the Gold Standard as an employee wellness framework based on concrete actions for companies to take in five key areas: establishing policies and programs to reduce cancer risk by prohibiting tobacco use and supporting tobacco cessation efforts; promoting physical activity, healthy nutrition and weight management; providing health insurance options that include detecting cancer at its earliest stages, access to quality care and participation in clinical trials; promoting employee awareness of these initiatives; and supporting the needs of cancer survivors in the workplace.

Nearly 200 private, nonprofit and government employers in a wide range of occupational categories have earned Gold Standard accreditation, including the National Cancer Institute (NCI) and a number of NCI-designated cancer centers.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing